Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Martina E. McMenamin"'
Autor:
Joshua Nealon, Yonatan M Mefsin, Martina E. McMenamin, Kylie E.C. Ainslie, Benjamin J. Cowling
Publikováno v:
Vaccine: X, Vol 17, Iss , Pp 100451- (2024)
Background: Waning of COVID-19 vaccine efficacy/effectiveness (VE) has been observed across settings and epidemiological contexts. We conducted a systematic review of COVID-19 VE studies and performed a meta-regression analysis to improve understandi
Externí odkaz:
https://doaj.org/article/f8cabf7e97144a8f9b3f8097046f2343
Autor:
Martina E, McMenamin, Joshua, Nealon, Yun, Lin, Jessica Y, Wong, Justin K, Cheung, Eric H Y, Lau, Peng, Wu, Gabriel M, Leung, Benjamin J, Cowling
Publikováno v:
The Lancet Infectious Diseases. 22:1435-1443
Hong Kong maintained low circulation of SARS-CoV-2 until a major community epidemic of the omicron (B.1.1.529) sublineage BA.2 began in January, 2022. Both mRNA (BNT162b2 [Fosun Pharma-BioNTech]) and inactivated CoronaVac (Sinovac, Beijing, China) va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb2a5ac37e3c01122a583a4bc76dbda9
https://doi.org/10.1016/s1473-3099(22)00345-0
https://doi.org/10.1016/s1473-3099(22)00345-0
Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong
Autor:
Martina E. McMenamin, Joshua Nealon, Yun Lin, Jessica Y. Wong, Justin K. Cheung, Eric H. Y. Lau, Peng Wu, Gabriel M. Leung, Benjamin J. Cowling
BackgroundHong Kong maintained extremely low circulation of SARS-CoV-2 until a major community epidemic of Omicron BA.2 starting in January 2022. Both mRNA BNT162b2 (BioNTech/Fosun Pharma) and inactivated CoronaVac (Sinovac) vaccines are widely avail
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f35b6c3e40bb40a34c7e5810c8b3609
https://doi.org/10.1101/2022.03.22.22272769
https://doi.org/10.1101/2022.03.22.22272769
Publikováno v:
Epidemiology (Cambridge, Mass.). 33(3)
When new vaccine components or platforms are developed, they will typically need to demonstrate noninferiority or superiority over existing products, resulting in the assessment of relative vaccine effectiveness (rVE). This review aims to identify ho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec41e2cb5fc891b23dd8f933d79c8517
https://pubmed.ncbi.nlm.nih.gov/35213508
https://pubmed.ncbi.nlm.nih.gov/35213508
Mixed outcome endpoints that combine multiple continuous and discrete components to form co-primary, multiple primary or composite endpoints are often employed as primary outcome measures in clinical trials. There are many advantages to joint modelli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::123720ebeac7898efe93e169f5e5b94f
Publikováno v:
Lancet (London, England)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbd7a5f00a05a323f750103e5391496a
https://doi.org/10.1016/s0140-6736(21)02288-1
https://doi.org/10.1016/s0140-6736(21)02288-1